Author: Business Wire

Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management

by  •  • 0 Comments

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Lily Nguyen as Director, Project Management, reporting to Kenneth Ruettimann, Ph.D., Aerie’s Vice President of Manufacturing. Ms. Nguyen will direct strategic plan development and

Read more →

Riassunto: BioTime annuncia una sovvenzione di 1,9 milioni di dollari statunitensi per l’ulteriore sviluppo di OpRegen® per il trattamento della degenerazione maculare secca

by  •  • 0 Comments

ALAMEDA, California–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), una società impegnata nello sviluppo clinico di biotecnologie per il trattamento di malattie degenerative, ha ottenuto un’altra sovvenzione per il 2018 d’importo massimo pari a 6,9 milioni di nuovi shekel israeliani (approssimativamente 1,9 milioni di dollari statunitensi) dall’Autorità per l’innovazione dello Stato d’Israele (Israel Innovation Authority, IIA). Tale sovvenzione è destinata all’ulteriore sviluppo di OpRege

Read more →

BioTime annonce une subvention de 1,9 million USD, destinée au développement continu de l’OpRegen® dans le traitement de la DMLA sèche

by  •  • 0 Comments

ALAMEDA, Californie–(BUSINESS WIRE)–BioTime, Inc. (NYSE American : BTX), une société de biotechnologie au stade clinique, axée sur les maladies dégénératives, a obtenu une nouvelle subvention pour 2018 à hauteur de 6,9 millions de nouveaux shekels israéliens (environ 1,9 million USD) de l’Autorité israélienne de l’Innovation (l’« IIA »). La subvention assure le financement du développement continu de l’OpRegen® ; et à ce jour, l’IIA a accordé des subventions annuelles couvrant plus de 13 mill

Read more →

BioTime erhält Zuschuss in Höhe von 1,9 Millionen US-Dollar für Weiterentwicklung von OpRegen® für Dry-AMD

by  •  • 0 Comments

ALAMEDA, Kalifornien–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), ein klinisches Biotechnologie-Unternehmen, das sich auf degenerative Erkrankungen spezialisiert, hat von der Israel Innovation Authority (IIA) für das Jahr 2018 eine Zusage für einen neuen Zuschuss von bis zu 6,9 Millionen Schekel (ca. 1,9 Millionen US-Dollar) erhalten. Die Mittel fließen in die Weiterentwicklung von OpRegen®, die von der IIA bis dato mit Zuschüssen von über 13 Millionen US-Dollar unterstützt wurde. OpRe

Read more →

Samenvatting: BioTime kent $1,9 miljoen subsidie toe aan de verdere ontwikkeling van OpRegen® voor Dry-AMD

by  •  • 0 Comments

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), een biotechnologisch bedrijf dat zich in de klinische fase toelegt op degeneratieve ziekten, heeft voor 2018 een nieuwe subsidie gekregen van maximaal 6,9 miljoen Israëlische Shekel (ongeveer 1,9 miljoen dollar) van de Israel Innovation Authority (het “IIA”). De subsidie voorziet in de financiering van de verdere ontwikkeling van OpRegen®. Tot op heden heeft het IIA jaarlijkse subsidies verstrekt voor een totaalbedrag van mee

Read more →

BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD

by  •  • 0 Comments

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million. OpRegen® is currently in a Phase I/IIa clinical study,

Read more →

Resumen: BioTime anuncia subvención de 1,9 millones de dólares para el desarrollo continuado de OpRegen® para la degeneración macular asociada con la edad de tipo seca

by  •  • 0 Comments

ALAMEDA, California–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), una empresa biotecnológica en fase clínica centrada en enfermedades degenerativas, ha obtenido una nueva beca para 2018 de hasta 6,9 millones de nuevos shéquels israelíes (aproximadamente 1,9 millones de dólares) de la Israel Innovation Authority (la “IIA”). La subvención ofrece financiación para el desarrollo continuado de OpRegen® y, hasta la fecha, la IIA ha ofrecido subvenciones anuales por un total de más de 13 millo

Read more →

BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites

by  •  • 0 Comments

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen®, with the addition of two new U.S. sites that are expected to begin treating patients later this quarter. “The addition of these two leading U.S. clinical trial sites is in addition to our current two sites in California. We are actively recruiting patients and are in li

Read more →

Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease

by  •  • 0 Comments

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multiple-ascending dose study of the Company’s hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer, AKB-4924. AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease (IBD). “Unlike other HIF stabilizers that mainly affect HIF-2 and stimulate erythropoiesi

Read more →